![]() |
|
|
Vol. 303, Issue 3, 1309-1316, December 2002
Department of Pharmacology and Toxicology, University of Kuopio,
Kuopio, Finland (M.H., P.T.M.); The Rockefeller University, New York,
New York (M.S., L.R.L., M.K.); and Department of Physiology and
Cellular Biophysics and Center for Neurobiology and Behavior, College
of Physicians and Surgeons, Columbia University, New York, New York
(J.A.G.)
Two different uptake processes terminate the synaptic action of
released catecholamines in brain: the high-affinity uptake to
presynaptic nerve terminals (uptake1, followed by oxidation by monoamine oxidase, MAO) or glial cells uptake (uptake2,
followed by O-methylation by
catechol-O-methyltransferase, COMT, and/or oxidation by
MAO). For dopaminergic neurons, uptake by the high-affinity dopamine
transporter (DAT) is the most effective mechanism, and the contribution
of glial COMT remains secondary under normal conditions. In the present
study we have characterized the role of COMT using COMT-deficient mice
in conditions where DAT is inhibited by
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)-piperazine (GBR 12909) or cocaine. In mice lacking COMT, GBR 12909 results in
total brain tissue dopamine levels generally higher than in wild-type
mice but no such potentiation was ever seen in striatal extracellular
fluid. Dopamine accumulation in nerve endings is more evident in
striatum and hypothalamus than in cortex. Both GBR 12909 and cocaine
induced hyperlocomotion in mice lacking COMT. Unexpectedly,
hyperactivity induced by 20 mg/kg GBR 12909 was attenuated only in male
COMT knockout mice, i.e., they had an inability to sustain the
hyperactivity induced by DAT inhibition. Furthermore, attenuation of
hyperlocomotion was observed also after cocaine treatment in both
C57BL/6 (at 5 and 15 mg/kg) and 129/Sv (at 30 mg/kg) genetic background
COMT-deficient male mice. Despite the possible interaction between DAT
and extraneuronal uptake (and subsequently COMT), the role of COMT in
dopamine elimination is still minimal in conditions when DAT is inhibited.
This article has been cited by other articles:
![]() |
X. Du, M. Schwander, E. M. Y. Moresco, P. Viviani, C. Haller, M. S. Hildebrand, K. Pak, L. Tarantino, A. Roberts, H. Richardson, et al. A catechol-O-methyltransferase that is essential for auditory function in mice and humans PNAS, September 23, 2008; 105(38): 14609 - 14614. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Kramer, T. Cunillera, E. Camara, J. Marco-Pallares, D. Cucurell, W. Nager, P. Bauer, R. Schule, L. Schols, A. Rodriguez-Fornells, et al. The Impact of Catechol-O-Methyltransferase and Dopamine D4 Receptor Genotypes on Neurophysiological Markers of Performance Monitoring J. Neurosci., December 19, 2007; 27(51): 14190 - 14198. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yacubian, T. Sommer, K. Schroeder, J. Glascher, R. Kalisch, B. Leuenberger, D. F. Braus, and C. Buchel Gene gene interaction associated with neural reward sensitivity PNAS, May 8, 2007; 104(19): 8125 - 8130. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Demiralp, C. S. Herrmann, M. E. Erdal, T. Ergenoglu, Y. H. Keskin, M. Ergen, and H. Beydagi DRD4 and DAT1 Polymorphisms Modulate Human Gamma Band Responses Cereb Cortex, May 1, 2007; 17(5): 1007 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bertolino, G. Blasi, V. Latorre, V. Rubino, A. Rampino, L. Sinibaldi, G. Caforio, V. Petruzzella, A. Pizzuti, T. Scarabino, et al. Additive Effects of Genetic Variation in Dopamine Regulating Genes on Working Memory Cortical Activity in Human Brain J. Neurosci., April 12, 2006; 26(15): 3918 - 3922. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Schott, C. I. Seidenbecher, D. B. Fenker, C. J. Lauer, N. Bunzeck, H.-G. Bernstein, W. Tischmeyer, E. D. Gundelfinger, H.-J. Heinze, and E. Duzel The Dopaminergic Midbrain Participates in Human Episodic Memory Formation: Evidence from Genetic Imaging J. Neurosci., February 1, 2006; 26(5): 1407 - 1417. [Abstract] [Full Text] [PDF] |
||||